What PKU HealthCare Corp.,Ltd.'s (SZSE:000788) P/E Is Not Telling You

With a price-to-earnings (or "P/E") ratio of 57.3x PKU HealthCare Corp.,Ltd. (SZSE:000788) may be sending very bearish signals at the moment, given that almost half of all companies in China have P/E ratios under 29x and even P/E's lower than 18x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.

With earnings growth that's exceedingly strong of late, PKU HealthCareLtd has been doing very well. It seems that many are expecting the strong earnings performance to beat most other companies over the coming period, which has increased investors’ willingness to pay up for the stock. If not, then existing shareholders might be a little nervous about the viability of the share price.

Check out our latest analysis for PKU HealthCareLtd

pe-multiple-vs-industry
SZSE:000788 Price to Earnings Ratio vs Industry February 28th 2024
Want the full picture on earnings, revenue and cash flow for the company? Then our free report on PKU HealthCareLtd will help you shine a light on its historical performance.
Advertisement

Does Growth Match The High P/E?

The only time you'd be truly comfortable seeing a P/E as steep as PKU HealthCareLtd's is when the company's growth is on track to outshine the market decidedly.

If we review the last year of earnings growth, the company posted a terrific increase of 67%. As a result, it also grew EPS by 24% in total over the last three years. Accordingly, shareholders would have probably been satisfied with the medium-term rates of earnings growth.

Comparing that to the market, which is predicted to deliver 41% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.

In light of this, it's alarming that PKU HealthCareLtd's P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.

The Key Takeaway

We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We've established that PKU HealthCareLtd currently trades on a much higher than expected P/E since its recent three-year growth is lower than the wider market forecast. Right now we are increasingly uncomfortable with the high P/E as this earnings performance isn't likely to support such positive sentiment for long. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

The company's balance sheet is another key area for risk analysis. You can assess many of the main risks through our free balance sheet analysis for PKU HealthCareLtd with six simple checks.

Of course, you might also be able to find a better stock than PKU HealthCareLtd. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SZSE:000788

PKU HealthCareLtd

Engages in the research and development, production, and sale of chemical pharmaceutical preparations, pharmaceutical distribution, and medical services in China.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

VA
valuebull
GOAI logo
valuebull on Eva Live ·

Is this the AI replacing marketing professionals?

Fair Value:US$7.4344.8% undervalued
26 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
ZA
PME logo
ZayaanS on Pro Medicus ·

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

Fair Value:AU$196.7832.6% undervalued
29 users have followed this narrative
5 users have commented on this narrative
18 users have liked this narrative
ST
WBD logo
SteveGruber on Warner Bros. Discovery ·

The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery  

Fair Value:US$18.1753.8% overvalued
5 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
PD
VRT logo
pdixit1 on Vertiv Holdings Co ·

The Infrastructure AI Cannot Be Built Without

Fair Value:US$408.6440.8% undervalued
33 users have followed this narrative
3 users have commented on this narrative
16 users have liked this narrative

Updated Narratives

KS
PME logo
ks3 on Pro Medicus ·

A stock I’m bullish on is Pro Medicus Limited (ASX: PME), an Australian healthcare technology company that develops medical imaging software

Fair Value:AU$199.733.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
KSS logo
Vestra on Kohl's ·

Kohl’s Corporation (KSS): The "Prestige-Value" Turnaround – Eyes on Tuesday’s Pre-Market Results.

Fair Value:US$19.5522.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VI
VNM logo
VietTrader on Vietnam Dairy Products ·

VNM: Market recovery expected, strong growth projected in 2026 with a target price of 76,800.

Fair Value:₫76.8k18.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.377.3% undervalued
50 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0229.7% undervalued
1100 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59631.4% undervalued
1297 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative